1. Home
  2. ZYME vs EVT Comparison

ZYME vs EVT Comparison

Compare ZYME & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.56

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EVT

Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$28.28

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
EVT
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2022
2003

Fundamental Metrics

Financial Performance
Metric
ZYME
EVT
Price
$26.56
$28.28
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $38.90
N/A
AVG Volume (30 Days)
★ 514.3K
79.4K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 33.33
N/A
EPS
N/A
★ N/A
Revenue
★ $105,965,000.00
N/A
Revenue This Year
$183.10
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 38.87
N/A
52 Week Low
$16.00
$23.00
52 Week High
$31.34
$29.65

Technical Indicators

Market Signals
Indicator
ZYME
EVT
Relative Strength Index (RSI) 47.51 45.27
Support Level $22.10 $26.98
Resistance Level $27.30 $29.45
Average True Range (ATR) 0.99 0.40
MACD -0.19 -0.05
Stochastic Oscillator 24.20 37.71

Price Performance

Historical Comparison
ZYME
EVT

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

Share on Social Networks: